Literature DB >> 2913547

Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children.

M H Lebel1, G H McCracken.   

Abstract

To determine the clinical importance of CSF cultures that are persistently positive for pathogens in patients treated for meningitis with the new cephalosporins, the records of 301 infants and children with bacterial meningitis enrolled prospectively in four clinical efficacy trials of cefuroxime or ceftriaxone therapy were reviewed. CSF culture results were positive for 20 patients and they were sterile at 18 to 36 hours after start of therapy for 281 patients. Seizures, subdural effusions, and hemiparesis were found significantly more often during hospitalization in those with delayed sterilization of CSF. Children with persistently positive cultures had a significantly higher incidence of neurologic abnormalities at the time of hospital discharge (45% v 19%) and at follow-up (41% v 13%) and of moderate to profound hearing impairment (35% v 15%) than did those with prompt sterilization of CSF. Repeat CSF examination is a useful prognostic indicator in infants and young children with bacterial meningitis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2913547

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  36 in total

Review 1.  Hearing impairment after bacterial meningitis: a review.

Authors:  H M Fortnum
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

Review 2.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

3.  Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis.

Authors:  Denis Grandgirard; Melchior Burri; Philipp Agyeman; Stephen L Leib
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

4.  High cerebrospinal fluid (CSF) penetration and potent bactericidal activity in CSF of NZ2114, a novel plectasin variant, during experimental pneumococcal meningitis.

Authors:  Christian Ostergaard; Dorthe Sandvang; Niels Frimodt-Møller; Hans-Henrik Kristensen
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

5.  Initial therapy for bacterial meningitis. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1990-02-15       Impact factor: 8.262

6.  Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis.

Authors:  F Fitoussi; C Doit; K Benali; S Bonacorsi; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

7.  Dexamethasone and bacterial meningitis in Pakistan.

Authors:  S A Qazi; M A Khan; N Mughal; M Ahmad; B Joomro; Y Sakata; N Kuriya; T Matsuishi; K A Abbas; F Yamashita
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

8.  Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.

Authors:  M E Falagas; L McDermott; D R Snydman
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

9.  Cerebrospinal fluid penetration of amikacin in children with community-acquired bacterial meningitis.

Authors:  J L Gaillard; C Silly; A Le Masne; B Mahut; F Lacaille; G Cheron; V Abadie; P Hubert; V Matha; C Coustere
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 10.  Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.

Authors:  Charles W Stratton
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.